SEC Filing Summary: AspenBio Pharma, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on July 29, 2011. The report details a corporate action involving the amendment of the Company's Articles of Incorporation to effect a reverse stock split. The Company is incorporated in Colorado and its Common Stock is listed on the NASDAQ Capital Market under the symbol APPY.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure change rather than financial performance results.
Material Changes
- Reverse Stock Split: Effective 12:01 a.m. on July 29, 2011, the Company executed a 1-for-5 reverse stock split. Each five (5) shares of common stock were combined into one (1) validly issued share.
- Fractional Shares: No fractional shares were issued; all fractions resulting from the split were rounded up to the nearest whole share.
- Trading Symbol: Concurrent with the split, a "D" was appended to the Company's trading symbol (APPY) on the NASDAQ Capital Market.
Outlook, Risks, and Management Commentary
The filing indicates that Nasdaq informed the Company the "D" designation would be removed on or after August 26, 2011. No additional management commentary, forward-looking guidance, or specific risk factors beyond the immediate impact of the stock split were disclosed in this document.
Key Facts for Investor Verification
- Verify the post-split share count and the rounding up of fractional shares in subsequent holdings statements.
- Confirm the removal of the "D" suffix from the APPY trading symbol after August 26, 2011.
- Review the filed "Articles of Amendment to Articles of Incorporation" (Exhibit 3.1) for the official legal language regarding the split.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.